Today, the U.S. Food and Drug Administration (FDA) announced the availability of a technical specifications document Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of a Drug. The specifications detailed in this guidance were built to support the data standards and processes described in the technical specifications document Study Data Technical Conformance Guide (March 2026).